相关期刊:《World Journal of Clinical Cases》《Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)》《Journal of Geriatric Cardiology》《Chinese Journal of Traumatology》更多>>
supported by the Vreden National Medical Research Center of Traumatology and Orthopaedics。
Purpose:Dabigatran is usually prescribed in recommended doses without monitoring of the blood coagulation for the prevention of venous thromboembolism after joint arthroplasty.ABCB1 is a key gene in the metabolism of ...
supported by the Chinese PLA Special Research on Health Care (17BJZ08)
BACKGROUND Uninterrupted use of oral anticoagulants before atrial fibrillation(AF)ablation can reduce the incidence of perioperative thromboembolic events.However,the effect of new oral anticoagulants on activated clo...
In recent years,the traditional concept that cirrhosis-related coagulopathy is an acquired bleeding disorder has evolved.Currently,it is known that in cirrhotic patients,the hemostatic system is rebalanced,which invol...
BACKGROUND The drug instructions for dabigatran recommend adjusting the dosage to 110 mg twice daily for patients with bleeding risk,and performing at least one renal function test per year for patients with moderate ...
Dabigatran,a direct thrombin inhibitor,has robust data for the treatment of deep venous thrombosis and pulmonary embolism,stroke prevention in non-valvular atrial fibrillation,and the prophylaxis of venous thromboembo...
BACKGROUND Most of the randomized clinical trials that led to the wide use of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation(AF)originated from western countrie...
Objective To investigate the relationship between estimated glomerular filtration rate (eGFR) and hemorrhage in elderly hypertensive patients complicated with non-valvular atrial fibrillation under dabigatran treatmen...
Objective To observe the efficacy of Dabigatran etexilate anticoagulation therapy and analyze its influencing factors in elderly patients.Methods The clinical data of the elderly patients using Dabigatran etexilate an...
supported by the Major New Drug Creation Program from National Science and Technology Major Project of China(2014ZX09303305).
Background Uncertainty remains regarding the association between body mass index(BMI)and the risk of bleeding in patients with non-valvular atrial fibrillation(NVAF).We aimed to investigate the association between BMI...
Background The direct oral anticoagulant dabigatran does not require any routine therapeutic drug monitoring.Yet,concerns about possible drug interactions susceptible to increase its inherent bleeding risk,especially ...